Our achievements in research projects made in close collaboration with our partners are published in peer reviewed journals.
News &
European Commission grants orphan drug designation for EVOCellic
Important milestone: EVOMEDIS has received Orphan Drug Designation from the European Medicines Agency (EMA) for its novel cell therapy drug for the treatment of severe burns.
Read More
Kleine Zeitung
Die Behandlung von Verbrennungswunden ist das Spezialgebiet des Start-ups EVOMEDIS, das sich aufgrund der exzellenten Wundtherapie-Expertise in Graz am ZWT angesiedelt hat.
Read More
Join our open clinical network and profit from our devolpment expertise.